Iowa City, IA Clinical Trials Report — June 2026

For Iowa City residents considering clinical trial participation, June 2026 presents a window of opportunity, particularly for those looking to join studies before enrollment closes. Across Iowa City, 545 clinical trials are currently recruiting across 117 research facilities, offering diverse avenues for contributing to medical progress.

Act quickly if you're interested in trials nearing their enrollment deadlines. A total of 33 clinical trials in Iowa City are scheduled to close within the next 90 days. Among these, 3 trials are still actively seeking healthy volunteers, providing a chance to participate in research without a specific medical condition.

Urgent Opportunities: Trials Closing Soon

Patients managing specific health conditions should note the following trials with impending deadlines. Conditions with trials closing soon include:

• Crohn's disease (2 trials)
• Carrier state (2 trials)
• Acute myeloid leukemia (1 trial)
• Adverse childhood experience (1 trial)
• AML (1 trial)
• AML with mutated NPM1 (1 trial)
• Atrial tachycardia (1 trial)
• Atrial arrhythmia (1 trial)
• Advanced breast cancer (1 trial)
• Chronic subdural hematoma (1 trial)

New Research Focuses on Weight Management and Diabetes

This month, Iowa City welcomed 2 new clinical trials, a decrease compared to the 8 trials that opened in May 2026. Both new studies are significant Phase 3 drug trials from a notable industry sponsor, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, focusing on chronic weight management, obesity, overweight, and type 2 diabetes mellitus.

• The "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)" study, NCT07654361, is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study. Sponsored by Gasherbrum Bio, Inc., this trial aims to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for participants with obesity or overweight and a weight-related comorbidity. It is designed for 3,600 participants.
• Also from Gasherbrum Bio, Inc., the "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)" trial, NCT07654374, is a randomized, double-blind, placebo-controlled Phase 3 study. This research will evaluate the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in 1,100 participants living with overweight or obesity and type 2 diabetes mellitus.

Both of these new trials include older adults, ensuring opportunities for senior populations to participate in this important research. One of these 2 new trials also accepts healthy volunteers, adding to the 59 total trials currently recruiting healthy participants in Iowa City.

Iowa City's Leading Research Facilities

Iowa City is a prominent research hub, largely driven by the extensive work conducted at the University of Iowa and its affiliated medical centers. These facilities consistently host the highest number of clinical trials, making them key destinations for individuals seeking to participate in medical research:

• University of Iowa (171 trials)
• University of Iowa/Holden Comprehensive Cancer Center (73 trials)
• University of Iowa Hospitals and Clinics (57 trials)
• University of Iowa Health Care (36 trials)
• University of Iowa Hospitals & Clinics (22 trials)
• Research Site (14 trials)
• University of Iowa Hospital and Clinics (11 trials)
• University of Iowa Stead Family Children's Hospital (8 trials)
• Iowa City VA Health Care System, Iowa City, IA (5 trials)
• The University of Iowa (5 trials)
• University of Iowa Hospital (4 trials)
• University of Iowa Healthcare (3 trials)

The University of Iowa system, including its comprehensive cancer center and children's hospital, clearly leads the research landscape in the city, offering a broad spectrum of studies across various medical specialties.

Expanding Your Search: Nearby Iowa Options

While Iowa City offers a robust selection of clinical trials, individuals in the wider Iowa region may also find opportunities in nearby communities. Other cities in Iowa with active trials include West Des Moines (3 trials), Ames (1 trial), Ankeny (1 trial), and Des Moines (1 trial).

June's clinical trial landscape in Iowa City highlights both immediate opportunities in closing studies and significant new research, particularly in metabolic health. As the research community continues its work, new avenues for participation will emerge, offering residents diverse ways to contribute to future medical advancements.